CN Patent

CN106795124A — 取代的1H‑吡唑并[3,4‑d]嘧啶类化合物的合成

Assigned to Sandoz AG · Expires 2017-05-31 · 9y expired

What this patent protects

本发明涉及通过使用从2,6‑二氯嘧啶羧酸开始制备的式(I)的中心1H‑吡唑并[3,4‑i]嘧啶来合成取代的双环化合物和中间体。本发明特别涉及合成Bruton酪氨酸激酶(Btk)抑制剂1‑((R)‑3‑(4‑氨基‑3‑(4‑苯氧基苯基)‑1H‑吡唑并[3,4‑d]嘧啶‑1‑基)哌啶‑1‑基)丙‑2‑烯‑1‑酮(依鲁替尼)及其合成中间体。

USPTO Abstract

本发明涉及通过使用从2,6‑二氯嘧啶羧酸开始制备的式(I)的中心1H‑吡唑并[3,4‑i]嘧啶来合成取代的双环化合物和中间体。本发明特别涉及合成Bruton酪氨酸激酶(Btk)抑制剂1‑((R)‑3‑(4‑氨基‑3‑(4‑苯氧基苯基)‑1H‑吡唑并[3,4‑d]嘧啶‑1‑基)哌啶‑1‑基)丙‑2‑烯‑1‑酮(依鲁替尼)及其合成中间体。

Drugs covered by this patent

Patent Metadata

Patent number
CN106795124A
Jurisdiction
CN
Classification
—
Expires
2017-05-31
Drug substance claim
No
Drug product claim
No
Assignee
Sandoz AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.